Zhong Guo Zheng Quan Bao·2026-01-09 12:19Group 1 - The AI healthcare sector showed strong performance on January 9, with multiple stocks experiencing significant gains, including Meinian Health (002044) hitting the daily limit, and Dean Diagnostics (300244) also reaching a "20CM" limit up [1] - The driving force behind this market movement is attributed to the announcement by OpenAI on January 8 regarding the launch of "ChatGPT Health," which offers health consultation and management services, seen as a direct competition to Ant Group's AI health application "Antifufu" [1] - "Antifufu" reported over 30 million monthly active users and more than 10 million daily health inquiries within a month of its latest version release, indicating high user acceptance and significant market potential for health AI in China [1] Group 2 - The capital market reacted quickly, with stocks like Yuyue Medical and Weining Health experiencing an initial rise following the release of the new version of "Antifufu" in December [2] - Companies such as Yuyue Medical and Sanofi Bio confirmed their collaboration with "Antifufu," reinforcing market expectations for industry chain synergy [2] - Industry experts believe that as domestic and international tech leaders invest heavily, the application of AI in healthcare will accelerate from the exploration phase to practical implementation, benefiting companies with established scenarios and clear commercialization paths [2]